168 related articles for article (PubMed ID: 34781271)
1. Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer.
Cilento MA; Poplawski NK; Paramasivam S; Thomas DM; Kichenadasse G
J Natl Compr Canc Netw; 2021 Nov; 19(11):1212-1217. PubMed ID: 34781271
[TBL] [Abstract][Full Text] [Related]
2. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
3. Targeting BRCA and PALB2 in Pancreatic Cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract][Full Text] [Related]
4. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of 84 PALB2 variants of uncertain significance.
Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
[TBL] [Abstract][Full Text] [Related]
6. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
7. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
Shen K; Yang L; Li FY; Zhang F; Ding LL; Yang J; Lu J; Wang NN; Wang Y
Curr Drug Targets; 2022; 23(2):145-155. PubMed ID: 34139979
[TBL] [Abstract][Full Text] [Related]
8. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
[TBL] [Abstract][Full Text] [Related]
10. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Gockley AA; Kolin DL; Awtrey CS; Lindeman NI; Matulonis UA; Konstantinopoulos PA
Gynecol Oncol; 2018 Aug; 150(2):219-226. PubMed ID: 29937315
[TBL] [Abstract][Full Text] [Related]
11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
13. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary Origin of Human
Chian JS; Li J; Wang SM
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511102
[No Abstract] [Full Text] [Related]
15. Cancer Risks Associated With Germline
Yang X; Leslie G; Doroszuk A; Schneider S; Allen J; Decker B; Dunning AM; Redman J; Scarth J; Plaskocinska I; Luccarini C; Shah M; Pooley K; Dorling L; Lee A; Adank MA; Adlard J; Aittomäki K; Andrulis IL; Ang P; Barwell J; Bernstein JL; Bobolis K; Borg Å; Blomqvist C; Claes KBM; Concannon P; Cuggia A; Culver JO; Damiola F; de Pauw A; Diez O; Dolinsky JS; Domchek SM; Engel C; Evans DG; Fostira F; Garber J; Golmard L; Goode EL; Gruber SB; Hahnen E; Hake C; Heikkinen T; Hurley JE; Janavicius R; Kleibl Z; Kleiblova P; Konstantopoulou I; Kvist A; Laduca H; Lee ASG; Lesueur F; Maher ER; Mannermaa A; Manoukian S; McFarland R; McKinnon W; Meindl A; Metcalfe K; Mohd Taib NA; Moilanen J; Nathanson KL; Neuhausen S; Ng PS; Nguyen-Dumont T; Nielsen SM; Obermair F; Offit K; Olopade OI; Ottini L; Penkert J; Pylkäs K; Radice P; Ramus SJ; Rudaitis V; Side L; Silva-Smith R; Silvestri V; Skytte AB; Slavin T; Soukupova J; Tondini C; Trainer AH; Unzeitig G; Usha L; van Overeem Hansen T; Whitworth J; Wood M; Yip CH; Yoon SY; Yussuf A; Zogopoulos G; Goldgar D; Hopper JL; Chenevix-Trench G; Pharoah P; George SHL; Balmaña J; Houdayer C; James P; El-Haffaf Z; Ehrencrona H; Janatova M; Peterlongo P; Nevanlinna H; Schmutzler R; Teo SH; Robson M; Pal T; Couch F; Weitzel JN; Elliott A; Southey M; Winqvist R; Easton DF; Foulkes WD; Antoniou AC; Tischkowitz M
J Clin Oncol; 2020 Mar; 38(7):674-685. PubMed ID: 31841383
[TBL] [Abstract][Full Text] [Related]
16. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
18. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
Grellety T; Peyraud F; Sevenet N; Tredan O; Dohollou N; Barouk-Simonet E; Kind M; Longy M; Blay JY; Italiano A
Ann Oncol; 2020 Jun; 31(6):822-823. PubMed ID: 32194151
[No Abstract] [Full Text] [Related]
20. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
